Insider Stock Trading History of Ingram Douglas S


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Ingram Douglas S since year 2005. The trader's CIK number is 1190644. At the time of this reporting, Ingram Douglas S is the President & CEO of Sarepta Therapeutics, Inc. . (stock ticker symbol SRPT). See this page for all insider trading activities at Sarepta Therapeutics, Inc. .

Note that in the past INGRAM DOUGLAS S also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Ingram Douglas S since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-11-08 SRPT Sarepta Therapeutics, Inc. Buy 38,138 52.44 1,999,956
2017-07-27 SRPT Sarepta Therapeutics, Inc. Buy 47,058 42.50 1,999,965
2014-02-21 AGN Allergan Inc Sale 0 125.70 0
2014-02-14 AGN Allergan Inc Option Ex 84,000 55.98 4,701,900
2014-02-14 AGN Allergan Inc Sale 84,000 124.40 10,449,432
2012-08-30 AGN Allergan Inc Sale 100,000 85.78 8,578,200
2012-08-30 AGN Allergan Inc Option Ex 100,000 36.15 3,615,000
2012-02-07 AGN Allergan Inc Option Ex 66,000 41.24 2,721,840
2012-02-07 AGN Allergan Inc Sale 66,000 86.38 5,700,750
2009-11-03 AGN Allergan Inc Option Ex 60,204 23.35 1,405,582
2009-11-03 AGN Allergan Inc Sale 60,204 56.45 3,398,816
2008-12-08 AGN Allergan Inc Sale 13,936 40.27 561,188
2008-12-08 AGN Allergan Inc Option Ex 22,420 16.69 374,257
2007-11-30 AGN Allergan Inc Sale 13,846 66.32 918,266
2007-11-29 AGN Allergan Inc Sale 1,100 66.00 72,600
2007-11-30 AGN Allergan Inc Option Ex 13,846 8.35 115,614
2007-11-29 AGN Allergan Inc Option Ex 1,100 8.35 9,185
2007-07-23 AGN Allergan Inc Option Ex 48 63.75 3,060
2007-07-23 AGN Allergan Inc Sale 48 63.76 3,060
2006-11-20 AGN Allergan Inc Option Ex 30,362 69.29 2,103,661
2006-11-20 AGN Allergan Inc Sale 30,362 120.03 3,644,350
2006-08-03 VLCM Volcom Inc Buy 2,500 19.25 48,137

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ingram Douglas S (President & CEO of Sarepta Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.